Concourse Financial Group Securities, Inc. Marker Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.52 Billion
  • Q1 2024
Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024
BUY
$3.63 - $5.46 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024
BUY
$2.4 - $5.75 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023
BUY
$3.59 - $8.78 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023
BUY
$3.59 - $8.78 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023
BUY
$0.78 - $4.25 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023
BUY
$0.28 - $3.12 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$0.24 - $0.41 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$0.3 - $0.56 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$0.26 - $0.46 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$0.37 - $1.0 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$0.95 - $1.72 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$1.68 - $2.88 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$1.88 - $3.56 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$1.47 - $3.29 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$1.36 - $1.75 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
SELL
$1.5 - $2.2 $28 - $41
-19 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$2.68 - $4.85 $50 - $92
19 New
19 $0
Q3 2019

Nov 13, 2019
SELL
$4.1 - $9.0 $77 - $171
-19 Closed
0 $0
Q4 2018

Feb 14, 2019
BUY
$4.2 - $9.74 $79 - $185
19 New
19 $0

Others Institutions Holding MRKR

# of Institutions
5
Shares Held
472K
Call Options Held
0
Put Options Held
0
View Full List

About Marker Therapeutics, Inc.

MRKR Quotes by TradingView
  • Ticker MRKR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,599,200
  • Market Cap $434M
  • Description
  • Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...
More about MRKR
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email